Another positive presentation. Now, 2022?
I listened and watched Christopher Missling's presentation. Once again, I searched diligently for any indications that Anavex 2-73 will fail in any of the several clinical trials underway.
Anavex 2-73 (blarcamesine) is targeted at otherwise recalcitrant or un-treatable central nervous system (CNS) diseases. Few systems in the body are more complex, more vulnerable to chemical (pharmaceutical) disruptions. Anyone watching the evening news broadcasts must sit through several minutes (several times) for "advertisements" of various new drugs.
Now, few of those target the CNS; but they do have minutes and paragraphs of stern warnings of all of the side effects that users must be aware of; including side effects that are lethal.
One pair of new cancer treatment drugs are advertised, claiming that users will "have a longer life." Of course, ever try to read the fine print at the bottom of those ads? I got up close to my 50-inch screen to read the lines of fine print. They are only on for an instant, but this pair of new cancer drugs, it was noted, appears to prolong cancer victim lives by about 3 to 5 months (as I recall, maybe less). (What do you suppose the drug costs per month of those 3 to 5 months might be?)
How does all of that relate to Anavex and Missling's presentation? A great deal.
First, before it can be approved and used therapeutically, a new drug — especially targeting the CNS — must show safety. Are the side effects so bad that they negate the positive clinical outcomes? Or, as bad as the side effects are, are the clinical results still so good that the side effects have to be endured?
Lastly, the new drug, simply, has to work. It has to reduce or prevent the targeted disease's bad symptoms to some degree.
Of course, this is why clinical trials are required, a) to reveal the extent of side effects ("adverse events"), and b) to demonstrate useful therapeutic outcomes (symptom suppression or prevention).
Anavex 2-73, once again, wins, on both accounts. No adverse events, side effects, were mentioned in any of the on-going clinical trails — because there are none of any consequence. In every one of the human clinical trials, Anavex 2-73 has been profoundly safe. Rare when treating the CNS. A profound plus.
But, what about efficacy? Are there any clinical data showing efficacy in humans with targeted diseases. Yep; very significant outcomes. Increases in cognition in patients with dementia.
Of course, those data derived from small, initial trials; insufficient in the number of patients and the duration of treatment to yet satisfy the FDA's strict conditions. For me, the keys are these.
Simply, Anavex 2-73 is both safe and efficacious. No disqualifying side effects, but profound clinical outcomes.
All of this will be formally affirmed, later, when the trials conclude. I continue to be confident in the future success of my modest investment in AVXL shares. From my start, several years ago, I could see 2023 to be the first full year when Anavex Life Sciences Corp attains full, successful operation as an expanding revenue-generating pharmaceutical.
I may have been wrong. It might well be in 2022.
Market Data 
Markets 
AI
